fda warning letter compounding semaglutide october 2025 Navigating Compounded Semaglutide: What Health Care Providers Need to Know Novo Nordisk protects US patients

The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk

In the digestive system, it slows gastric emptying the rate at which food leaves the stomach prolonging feelings of fullness and reducing the postprandial blood sugar spikes that drive hunger and cravings

The GIP receptor component enhances insulin secretion and may reduce nausea associated with GLP-1 activation

Dose reduction for side effects If a dose increase triggers side effects that do not improve after two to three weeks, stepping back down to the previous dose is the standard approach